Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Approvals Clinical Trials

Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

Dr Reddy’s, Lupin, Cipla And Sun Pharma Partner With Eli Lilly For Baricitinib In India

  • News

Executive Summary

After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

Table

View full table

Topics

Related Companies

Tags:
Coronavirus COVID-19 Approvals Clinical Trials
Latest Headlines

Henlius Reports Revenue Rise For First Quarter Of 2024

Boehringer Secures FDA Approval For High-Concentration Cyltezo – But Without Interchangeability

European Progress On Biosimilars Is Just The Beginning

Supply Chain Derisking: The Case For US-India Partnering Amid China Clout

See All
UsernamePublicRestriction

Register

GB151024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By